Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Iambic logo — Better technology for better medicines | Nasdaq: IAM

Iambic

Better technology for better medicines | Nasdaq: IAM

Founded 2019 United States San Diego, United States 194 employees Total: $303.00M AI, Biotechnology +2

General Information

Company Name Iambic
Founded Year 2019
Location United States San Diego, United States
Employees 194
Industries AI, Biotechnology, Health and Wellness +1
Business Model B2B, Platform
Revenue Model Licensing, Performance Based, Project Based
Social

BounceWatch is an independent company data service, not affiliated with Iambic. To contact Iambic, visit iambic.ai.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Iambic compare?

A PDF of Iambic and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Iambic soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Oct 26, 2026

Iambic presented updated clinical data for IAM1363 in a poster presentation at ESMO 2026.

IPO Announced Oct 15, 2026

Iambic has gone public, trading on #Nasdaq under the ticker #IAM.

Iambic a competitor of yours? Have our desk watch it

About Iambic

Iambic, founded in 2019 and headquartered in the United States, is a clinical-stage life sciences and technology company. With the slogan "Charting new paths to superior medicines", Iambic leverages an AI-driven platform to develop novel medicines. The company has swiftly demonstrated its capability to advance new drug candidates to human clinical trials across diverse target classes and mechanisms of action.

Based in San Diego, Iambic has brought together top-tier AI experts and seasoned drug developers. The company operates within the AI, Biotechnology, Health and Wellness, and Machine Learning industries, focusing on a disease-agnostic pipeline to meet pressing patient needs.

Having secured a substantial $100 million in a Late VC investment on 01 November 2025, Iambic is backed by a prestigious group of investors, including Abingworth, Illumina Ventures, Tao Capital Partners, and others. This robust financial support underscores the investor confidence in Iambic's innovative approach and promising pipeline.

Business keywords: AI-driven drug discovery, Clinical-stage life sciences, Novel medicine development, Therapeutics innovation, Disease-agnostic pipeline, First-in-class medicines, Best-in-class medicines, Drug hunters, AI experts in healthcare, Unmet patient need, Clinical trials, Drug candidates, Mechanisms of action, Pharmaceutical R&D

Services & Products

Development of AI-driven drug discovery platforms
Optimization of drug candidates
Production of first-in-class and best-in-class therapeutics

Target Customers

Pharmaceutical companies Biotechnology firms Healthcare professionals involved in oncology Research institutions focused on drug discovery

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Late VC $100.00M 17
Abingworth Illumina Ventures Tao Capital Partners
Abingworth, Illumina Ventures +15
01 Nov 2025
Series B $50.00M 5
Abingworth Illumina Ventures Qatar Investment Authority
Abingworth, Illumina Ventures +3
01 Jun 2024
Series B $100.00M 11
Coatue Abingworth Illumina Ventures
Coatue, Abingworth +9
01 Oct 2023
Series A $53.00M 6
OrbiMed Catalio Capital Management Freeflow Ventures
OrbiMed, Catalio Capital Management +4
01 Jul 2021
Spinout Undisclosed 2
University of Bristol Enterprise Fund
University of Bristol Enterprise Fund, Imperial College London
01 Jan 2019

Iambic Alternatives & Competitors

View All Alternatives
Iambic vs
Oxford BioTherapeutics
Oxford BioTherapeutics United Kingdom

Redefining the cancer-immune synapse for novel immune checkpoint mechanisms

66 employees
Biotechnology, Health Care
Compare Iambic vs Oxford BioTherapeutics
Iambic vs
Model Medicines
Model Medicines United States

Precision Medicines, Broad Applications

Seed
15 employees
AI, Biotechnology
Compare Iambic vs Model Medicines
Iambic vs
Applied Therapeutics, Inc.
Applied Therapeutics, Inc. United States

Applied Therapeutics is a clinical-stage biopharmaceutical company that uses our novel drug-developm...

Post-IPO Equity
45 employees
Biotechnology, Health Care
View all alternatives

FAQ About Iambic

Better technology for better medicines | Nasdaq: IAM
Iambic was founded in 2019.
Iambic is headquartered in San Diego, United States.
Iambic operates in AI, Biotechnology, Health and Wellness and Machine Learning. Its work centres on AI-driven drug discovery, Clinical-stage life sciences, Novel medicine development and Therapeutics innovation. Its customers include Pharmaceutical companies, Biotechnology firms and Healthcare professionals involved in oncology.
Iambic has a B2B and Platform business model. Its revenue comes from Licensing, Performance Based and Project Based.
Iambic has approximately 194 employees.
Iambic has completed 5 funding rounds, raising a total of $303.00M.
Iambic offers: Development of AI-driven drug discovery platforms, Optimization of drug candidates, Production of first-in-class and best-in-class therapeutics.
Top alternatives and competitors to Iambic include Oxford BioTherapeutics, Model Medicines, Applied Therapeutics, Inc., MitoRx Therapeutics, Acrivon Therapeutics, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Iambic and Oxford BioTherapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Iambic, https://bouncewatch.com/company/iambic-therapeutics, updated 5 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout